Tempus AI director David Epstein sells $46,361 in shares

Published 19/03/2025, 23:32
Tempus AI director David Epstein sells $46,361 in shares

David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 990 shares of the company’s Class A Common Stock. The artificial intelligence company, currently valued at $7.9 billion, has seen its stock perform strongly with a 42% gain year-to-date according to InvestingPro data. The transaction, executed on March 17, 2025, was completed at a price of $46.83 per share, totaling approximately $46,361. The stock currently trades at $48.03, slightly above the insider’s sale price. This sale was conducted under a Rule 10b5-1 trading plan, which Epstein adopted on August 27, 2024. Following the transaction, Epstein holds 26,284 shares directly. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.29, while operating with moderate debt levels. Additional insights and 7 more key ProTips are available with an InvestingPro subscription.

In other recent news, Tempus AI reported a significant 35.8% increase in revenue for the fourth quarter of 2024, reaching $700 million. However, the company’s earnings per share stood at -0.18, which may have influenced investor sentiment. Tempus AI has also revised its revenue guidance for 2025 to approximately $1.24 billion, incorporating contributions from its recent acquisition of Ambry Genetics. This acquisition is expected to enhance Tempus’s capabilities in AI-driven research platforms and expand its network in the healthcare sector. Stifel analysts maintained a Hold rating on Tempus AI, with a price target of $65, following the company’s earnings report. Meanwhile, JPMorgan downgraded Tempus AI from Overweight to Neutral but raised the price target to $55, citing the company’s recent earnings and valuation concerns. Additionally, Tempus AI has launched the Olivia AI personal health app, marking its entry into consumer health technology. These developments indicate Tempus AI’s ongoing strategic growth and expansion efforts in the healthcare technology industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.